The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?

We investigated the prognostic value of some variables of effective ketoconazole treatment for metastatic castration-resistant prostate cancer (mCRPC). In total, 163 patients with mCRPC were eligible, receiving ketoconazole 200–400 mg three times daily with replacement doses of prednisone. Progressi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lin, Guo-Wen, Yao, Xu-Dong, Ye, Ding-Wei, Zhu, Yao, Zhang, Shi-Lin, Dai, Bo, Zhang, Hai-Liang, Shen, Yi-Jun, Ma, Chun-Guang
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3734980/
https://ncbi.nlm.nih.gov/pubmed/22902911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aja.2012.57
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires